Lungcancer

Lung cancer is the leading cause of cancer-related mortality worldwide, accounting for nearly one-fifth of all oncology deaths annually. Originating primarily in the epithelial lining of the respiratory tract, lung carcinomas develop through a multistep process driven by genetic alterations and environmental exposures.

Historically diagnosed at advanced stages with limited treatment options, the clinical landscape of lung cancer has been transformed by early screening protocols, high-resolution imaging, and comprehensive molecular profiling. Understanding the biological mechanisms, histological categories, and diagnostic frameworks of lung cancer is essential for effective clinical management and risk stratification.

1. Pathophysiology and Etiology

Lung cancer arises from malignant transformation of bronchial or alveolar epithelial cells. Carcinogenesis is initiated by chronic exposure to inhaled mutagens, leading to cumulative genetic mutations in proto-oncogenes and tumor suppressor genes.

                      [ Chronic Inhaled Carcinogen Exposure ]
                     (Tobacco Smoke, Radon, Asbestos, Pollution)
                                          │
                                          ▼
                   [ DNA Damage & Cumulative Genetic Mutations ]
                   (Inactivation of p53, RB1; Activation of KRAS, EGFR)
                                          │
                                          ▼
                      [ Bronchial / Alveolar Epithelial Atypia ]
                         (Squamous Metaplasia or AAH)
                                          │
                                          ▼
                        [ Invasive Carcinoma Development ]
                                          │
      ┌───────────────────────────────────┴───────────────────────────────────┐
      ▼                                                                       ▼
[ Local Invasion ]                                                  [ Metastatic Dissemination ]
(Bronchial obstruction, pleural effusion)                           (Regional lymph nodes, brain, bone, liver)

Etiological Drivers

Tobacco Smoking: The single greatest risk factor, responsible for approximately 85% of all lung cancer cases. Tobacco smoke contains over 60 established carcinogens (including nitrosamines, polycyclic aromatic hydrocarbons, and benzopyrene) that directly cause DNA adduct formation and cross-linking.
Environmental Exposures: Radon gas exposure (the leading cause of lung cancer in non-smokers), occupational exposure to asbestos, arsenic, beryllium, chromium, and ambient fine particulate matter ( $\text{PM}_{2.5}$ PM2.5).
Oncogenic Driver Mutations: In a significant subset of non-smokers, lung adenocarcinoma develops independently of tobacco exposure via specific activating driver mutations, including EGFR (epidermal growth factor receptor) mutations, ALK (anaplastic lymphoma kinase) gene rearrangements, ROS1 fusions, and KRAS alterations.

2. Histological Classification and Subtypes

The World Health Organization (WHO) divides lung cancer into two primary histological categories based on cell morphology, clinical behavior, and therapeutic response: Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).

                                [ Lung Carcinomas ]
                                         │
      ┌──────────────────────────────────┴──────────────────────────────────┐
      ▼                                                                     ▼
[ Non-Small Cell Lung Cancer (NSCLC) ~85% ]                     [ Small Cell Lung Cancer (SCLC) ~15% ]
• Adenocarcinoma                                                • Neuroendocrine origin
• Squamous Cell Carcinoma                                       • Rapid doubling time / early metastasis
• Large Cell Carcinoma                                          • Strongly linked to heavy smoking

1. Non-Small Cell Lung Cancer (NSCLC)

Accounts for approximately 85% of all lung cancer diagnoses and encompasses three major histological subtypes:

Adenocarcinoma (~40–50% of cases): The most common subtype overall, and the predominant form seen in non-smokers and women. Typically arises in peripheral lung parenchyma from type II pneumocytes or Clara cells, presenting as gland-forming, mucin-producing lesions.
Squamous Cell Carcinoma (~20–30% of cases): Strongly correlated with heavy tobacco abuse. Arises centrally within major lobar or segmental bronchi, characterized histologically by keratin pearls, intercellular bridges, and central cavitation due to tumor necrosis.
Large Cell Carcinoma (~5–10% of cases): An undifferentiated malignant epithelial tumor lacking clear architectural features of squamous or glandular differentiation; tends to be aggressive and centrally located.

2. Small Cell Lung Cancer (SCLC)

Accounts for approximately 15% of lung cancers. SCLC is a highly aggressive neuroendocrine tumor originating from bronchial Feyrter (Kulchitsky) cells. Histologically, it displays small, dark blue cells with scant cytoplasm, granular nuclear chromatin (“salt-and-pepper” appearance), high mitotic rates, and extensive necrosis. SCLC is characterized by rapid doubling times and early, widespread systemic metastasis.

Histological Subtype	Primary Anatomic Location	Associated Biomarkers / Features	Relative Prevalence
Adenocarcinoma	Peripheral lung parenchyma	Thyroid Transcription Factor-1 (TTF-1), Cytokeratin 7 (CK7)	40–50%
Squamous Cell Carcinoma	Central (lobar/segmental bronchi)	p63, p40, Cytokeratin 5/6 (CK5/6), central cavitation	20–30%
Small Cell Carcinoma	Central / mediastinal masses	Synaptophysin, Chromogranin A, CD56, high Ki-67 index	~15%

3. Clinical Presentation and Paraneoplastic Syndromes

Clinical features depend on tumor location, local invasion, regional lymphatic spread, and systemic metastasis:

Central Lesions (e.g., Squamous Cell, SCLC): Present with persistent cough, hemoptysis, post-obstructive atelectasis, recurrent localized pneumonia, or dyspnea.
Peripheral Lesions (e.g., Adenocarcinoma): Frequently asymptomatic in early stages; discovered incidentally on chest imaging or presenting with pleuritic chest pain and pleural effusions due to chest wall involvement.
Pancoast (Superior Sulcus) Tumors: Apical lung tumors that invade local neural and vascular structures, leading to brachial plexus neuropathy (shoulder and arm pain) and Horner Syndrome (ipsilateral ptosis, miosis, and anhidrosis due to sympathetic chain compression).

Paraneoplastic Syndromes

Lung cancers frequently produce systemic hormones or antibodies that cause distant organ manifestations:

SCLC: Ectopic production of Adrenocorticotropic Hormone (ACTH) causing Cushing syndrome, Antidiuretic Hormone (ADH) causing the Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH with severe hyponatremia), or autoantibody production causing Lambert-Eaton Myasthenic Syndrome (neuromuscular junction weakness).
Squamous Cell Carcinoma: Ectopic secretion of Parathyroid Hormone-related Protein (PTHrp), causing severe hypercalcemia of malignancy.
Adenocarcinoma: Hypercoagulable states (Trousseau Syndrome of migratory thrombophlebitis) and Hypertrophic Osteoarthropathy (digital clubbing accompanied by periostitis of long bones).

4. Diagnostic Workup, Staging, and Molecular Profiling

Accurate management requires tissue acquisition for histological confirmation, comprehensive staging, and broad molecular testing.

                  [ Clinical Suspicion or Screening Nodule ]
                                     │
                                     ▼
                [ Diagnostic Imaging: Chest CT with Contrast ]
                                     │
                                     ▼
           [ Tissue Acquisition & Biopsy (Bronchoscopy / CT-guided) ]
                                     │
      ┌──────────────────────────────┴──────────────────────────────┐
      ▼                                                             ▼
[ Histological Subtyping ]                             [ Staging & Biomarker Panel ]
• Differentiates NSCLC vs. SCLC                        • Whole-body PET/CT & Brain MRI
• Immunohistochemistry (TTF-1, p40)                     • Molecular profiling (EGFR, ALK, PD-L1)

Diagnostic Imaging: Contrast-enhanced Computed Tomography (CT) evaluates the primary tumor size and locoregional lymph nodes. Positron Emission Tomography (PET-CT) using 18F-FDG evaluates regional lymph node involvement and distant metastases. Brain MRI is essential due to the high propensity of lung cancer to metastasize to the central nervous system.
Tissue Acquisition: Obtained via flexible bronchoscopy with endobronchial ultrasound (EBUS) for central/mediastinal lesions, or transthoracic CT-guided needle biopsy for peripheral masses.
Anatomic Staging: NSCLC uses the TNM Classification System (Tumor size/extent, Nodal involvement, Metastasis) to assign Stages I through IV. SCLC is historically staged using the Veterans Administration Lung Study Group system as either Limited-Stage (confined to one hemithorax, safely encompassable in a single radiation portal) or Extensive-Stage (metastatic spread beyond one hemithorax).
Molecular Profiling: For non-squamous NSCLC, advanced diagnostic protocols mandate Next-Generation Sequencing (NGS) to identify actionable genomic mutations (such as EGFR, ALK, ROS1, BRAF, RET, MET, and KRAS G12C) alongside PD-L1 immunohistochemistry expression testing.

Conclusion

Lung cancer remains a complex oncological challenge defined by distinct histological features, varied genetic drivers, and aggressive physiological behaviors. Through early diagnostic detection, comprehensive TNM staging, precise neuroendocrine/epithelial subtyping, and routine molecular biomarker profiling, clinical teams can accurately phenotype tumors to deliver targeted, personalized therapeutic strategies.